Envoy Medical: Dr. Haring-Smith resigns from board; Michael Crowe appointed

Envoy Medical, Inc.

Dr. Whitney Haring-Smith resigned effective June 6, 2024; no disagreement.
Board appointed Michael Crowe on June 7, 2024 to fill vacancy.
Crowe receives $40k annual cash and 25,000-share option award vesting over 4 years.
Crowe is SVP Operations at Bioventus, former VP Operations at Abbott Vascular.
Envoy expects to begin pivotal clinical study for Acclaim CI later in 2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Crowe

Director

COCH · Envoy Medical, Inc.

Effective: 2024-06-07
Filed: June 11, 2024, 7:59 PM ET

On June 7, 2024, the Board appointed Michael Crowe to fill the vacancy created by Dr. Haring-Smith’s resignation.

Departed

Whitney Haring-Smith

Director

COCH · Envoy Medical, Inc.

Effective: 2024-06-06
Successor: Michael Crowe
Filed: June 11, 2024, 7:59 PM ET

On June 6, 2024, Dr. Whitney Haring-Smith, notified the Company of his decision to resign from the board of directors of the Company (the “Board”) effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Crowe was appointed as Director at Envoy Medical, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 7, 2024, the Board appointed Michael Crowe to fill the vacancy created by Dr. Haring-Smith’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Whitney Haring-Smith resigned as Director at Envoy Medical, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 6, 2024, Dr. Whitney Haring-Smith, notified the Company of his decision to resign from the board of directors of the Company (the “Board”) effective immediately.

View on SEC.gov

Envoy Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-051511

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.